VLPs containing stalk domain and ectodomain of matrix protein 2 of influenza induce protection in mice
Open Access
- 27 February 2023
- journal article
- research article
- Published by Springer Nature in Virology Journal
- Vol. 20 (1) , 1-9
Abstract
Background: As a result of antigenic drift, current influenza vaccines provide limited protection against circulating influenza viruses, and vaccines with broad cross protection are urgently needed. Hemagglutinin stalk domain and ectodomain of matrix protein 2 are highly conserved among influenza viruses and have great potential for use as a universal vaccine. Methods: In this study, we co-expressed the stalk domain and M2e on the surface of cell membranes and generated chimeric and standard virus-like particles of influenza to improve antigen immunogenicity. We subsequently immunized BALB/c mice through intranasal and intramuscular routes. Results: Data obtained demonstrated that vaccination with VLPs elicited high levels of serum-specific IgG (approximately 30-fold higher than that obtained with soluble protein), induced increased ADCC activity to the influenza virus, and enhanced T cell as well as mucosal immune responses. Furthermore, mice immunized by VLP had elevated level of mucosal HA and 4M2e specific IgA titers and cytokine production as compared to mice immunized with soluble protein. Additionally, the VLP-immunized group exhibited long-lasting humoral antibody responses and effectively reduced lung viral titers after the challenge. Compared to the 4M2e-VLP and mHA-VLP groups, the chimeric VLP group experienced cross-protection against the lethal challenge with homologous and heterologous viruses. The stalk domain specific antibody conferred better protection than the 4M2e specific antibody. Conclusion: Our findings demonstrated that the chimeric VLPs anchored with the stalk domain and M2e showed efficacy in reducing viral loads after the influenza virus challenge in the mice model. This antibody can be used in humans to broadly protect against a variety of influenza virus subtypes. The chimeric VLPs represent a novel approach to increase antigen immunogenicity and are promising candidates for a universal influenza vaccine.Keywords
All Related Versions
Funding Information
- Zhejiang Provincial Natural Science Foundation of China (LGF21H300006, LGF20C010002)
This publication has 27 references indexed in Scilit:
- Cooperativity Between CD8+ T Cells, Non-Neutralizing Antibodies, and Alveolar Macrophages Is Important for Heterosubtypic Influenza Virus ImmunityPLOS Pathogens, 2013
- Universal Vaccine Based on Ectodomain of Matrix Protein 2 of Influenza A: Fc Receptors and Alveolar Macrophages Mediate ProtectionThe Journal of Immunology, 2011
- Intranasal Immunization with Influenza VLPs Incorporating Membrane-Anchored Flagellin Induces Strong Heterosubtypic ProtectionPLOS ONE, 2010
- Influenza Virus Vaccine Based on the Conserved Hemagglutinin Stalk DomainmBio, 2010
- Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developmentsExpert Review of Vaccines, 2009
- A “universal” human influenza A vaccineVirus Research, 2004
- Effectiveness and Cost-Benefit of Influenza Vaccination of Healthy Working AdultsJAMA, 2000
- Evolution of influenza A and B viruses: conservation of structural features in the hemagglutinin genes.Proceedings of the National Academy of Sciences, 1982
- Cloning and DNA sequence of double-stranded copies of haemagglutinin genes from H2 and H3 strains elucidates antigenic shift and drift in human influenza virusNature, 1980
- Complete structure of the hemagglutinin gene from the human influenza A/Victoria/3/75 (H3N2) strain as determined from cloned DNACell, 1980